JDJudith A. Drazba

Judith A. Drazba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Judith A. Drazba has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Leronlimab Inhibits Colon Carcinoma Metastasis in a Humanized Mouse Xenograft Model

    by Daniel J. Lindner, Judith A. Drazba, Yvonne A. Parker, Kathryn Guinta, Amy Graham, Patricia A. Parsons-Wingerter, Rita Pancsa, Richard G. Pestell, Denis R. Burger

    Leronlimab, a humanized monoclonal antibody directed to the CCR5 receptor, demonstrated anti-tumor activity in humanized NSG mouse models of both heterotopic and orthotopic SW480 human colon carcinoma. The anti-tumor effect was lost in non-humanized mice, suggesting a critical role for engrafted human leukocytes. Development of xGVHD was delayed in both tumor-bearing and non-tumor-bearing mice that had been treated with leronlimab. Leronlimab induced human CD4+CD25+ cells in the peripheral blood of tumor-bearing (1.5-fold increase, p=0.016) and non-tumor-bearing animals (2.2-fold, p=0.0038). Leronlimab reduced CD4+CD25- cells (1.84-fold reduction, p=0.033). In the orthotopic colon cancer model, lung metastatic burden was decreased ~87% in leronlimab-treated mice compared to IgG-treated animals (p=0.012). Blockade of CCR5 signaling reduced peri-tumoral vessel formation feeding the tumor, 62% (p=0.013). As CD4+CD25+ T cells, play a crucial role in immune checkpoint inhibitor (ICI) responses we assessed CCR5/immune checkpoint gene expression in human colon cancer. CCR5 and its ligands were overexpressed in human colon cancer, correlating with increased immune checkpoint gene expression in both microsatellite stable (MSS) and instable (MSI) patients.


  • Open Access

    Trafficking and Association of Plasmodium falciparum MC-2TM with the Maurer’s Clefts

    by Raghavendra Yadavalli, John W. Peterson, Judith A. Drazba, Tobili Y. Sam-Yellowe

    In this study, we investigated stage specific expression, trafficking, solubility and topology of endogenous PfMC-2TM in P. falciparum (3D7) infected erythrocytes. Following Brefeldin A (BFA) treatment of parasites, PfMC-2TM traffic was evaluated using immunofluorescence with antibodies reactive with PfMC-2TM. PfMC-2TM is sensitive to BFA treatment and permeabilization of infected erythrocytes with streptolysin O (SLO) and saponin, showed that the N and C-termini of PfMC-2TM are exposed to the erythrocyte cytoplasm with the central portion of the protein protected in the MC membranes. PfMC-2TM was expressed as early as 4 h post invasion (hpi), was tightly colocalized with REX-1 and trafficked to the erythrocyte membrane without a change in solubility. PfMC-2TM associated with the MC and infected erythrocyte membrane and was resistant to extraction with alkaline sodium carbonate, suggestive of protein-lipid interactions with membranes of the MC and erythrocyte. PfMC-2TM is an additional marker of the nascent MCs.


  • Open Access

    Sex, androgens and regulation of pulmonary AR, TMPRSS2 and ACE2

    by Mehdi Baratchian, Jeffrey M. McManus, Mike Berk, Fumihiko Nakamura, Sanjay Mukhopadhyay, Weiling Xu, Serpil Erzurum, Judy Drazba, John Peterson, Eric A. Klein, et al.

    The sex discordance in COVID-19 outcomes has been widely recognized, with males generally faring worse than females and a potential link to sex steroids. A plausible mechanism is androgen-induced expression of TMPRSS2 and/or ACE2 in pulmonary tissues that may increase susceptibility or severity in males. This hypothesis is the subject of several clinical trials of anti-androgen therapies around the world. Here, we investigated the sex-associated TMPRSS2 and ACE2 expression in human and mouse lungs and interrogated the possibility of pharmacologic modification of their expression with anti-androgens. We found no evidence for increased TMPRSS2 expression in the lungs of males compared to females in humans or mice. Furthermore, in male mice, treatment with the androgen receptor antagonist enzalutamide did not decrease pulmonary TMPRSS2. On the other hand, ACE2 and AR expression was sexually dimorphic and higher in males than females. ACE2 was moderately suppressible with enzalutamide therapy. Our work suggests that sex differences in COVID-19 outcomes attributable to viral entry are independent of TMPRSS2. Modest changes in ACE2 could account for some of the sex discordance.


  • Open Access

    Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin)

    by Kamini Singh, Arishya Sharma, Maria C Mir, Judith A Drazba, Warren D Heston, Cristina Magi-Galluzzi, Donna Hansel, Brian P Rubin, Eric A Klein, Alexandru Almasan

    Macroautophagy is a catabolic process that can mediate cell death or survival. Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) treatment (TR) is known to induce autophagy. Here we investigated whether SQSTM1/p62 (p62) overexpression, as a marker of autophagic flux, was related to aggressiveness of human prostate cancer (PCa) and whether autophagy regulated the treatment response in sensitive but not resistant PCa cell lines.